Health and wellness company Rapid Nutrition plc (Euronext Growth Paris:ALRPD) announced on Tuesday that it has been chosen as a key partner in the Osteoarthritis Prevention Study (TOPS) led by Wake Forest University.
This project, receiving USD17.1m in funding from major health organisations, is the largest investigation into osteoarthritis prevention through weight loss and exercise in women. The five-year study, led by Wake Forest University's Department of Health and Exercise Science, aims to enrol 1,230 women aged 50 and above, focusing on those at risk of osteoarthritis due factors such as overweight status.
Rapid Nutrition's participation underscores its commitment to advancing scientific research and promoting women's health globally, the company said.
Eli Lilly's Omvoh receives US FDA approval
Axcynsis Therapeutics' IND for AT03-65 receives US FDA approval
Innovent Biologics' IBI343 receives Breakthrough Therapy Designation in China
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Johnson & Johnson submits New Drug Application for TAR-200 to treat bladder cancer
GenSight Biologics reports positive five-year results for LUMEVOQ gene therapy in LHON Patients
Futura Medical plc reports positive results from WSD4000 Home User Study
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Sen-Jam Pharmaceutical receives ethics approval for Australian clinical trial of SJP-001
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
Kelker Pharma introduces NUTRILINQ for patients using weight loss drugs
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
BioArctic reports FDA acceptance of BLA for for subcutaneous maintenance dosing of Leqembi
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing